Can Novo, Lilly Take Credit for U.S. Obesity Rate Decline?
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Futu Morning Post | Fund managers are entering the Chinese stock market at a record speed! The 'China Dragon' ETF lands in the US stock market; foreign capital accelerates its positions! Morgan Stanley increases its shareholding in BYD and other companies
The size of the USA money market fund has reached a record $6.46 trillion; Biden's vague stance has sparked an energy storm, causing international oil prices to soar by over 5%; just after raising funds, OpenAI secured a $4 billion credit line, with liquid assets exceeding over $10 billion.
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, causing "平替" manufacturer Hims & Hers to drop nearly 10%.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Deutsche Bank Reiterates Buy on Eli Lilly, Maintains $1025 Price Target
Eli Lilly Analyst Ratings
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
BofA's Top 10 Growth Stocks for October
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
4 Stocks to Watch on Thursday: STZ, LLY and More
U.S. Tweaks 2025 Medicare Price Negotiation Process
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
"Cash is king" is outdated, these assets are more worth buying.
The outlook for cash assets is becoming bleak, and a rate cut by the Federal Reserve will erode the yield of cash assets.
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024